[
  {
    "sentence": "Case 1\nCase 2\n\n\n\n\nAge at Diagnosis\n\n55\n74\n\n\n\nSex\n\nF\nM\n\n\n\nDiagnosis\n\nMDS with EB-2, with hypocellular AML transformation/progression\nMyeloid neoplasm with ringed sideroblasts\n\n\n\nBone marrow blasts (%)\n\n15% at diagnosis50% at AML transformation\n5-7%\n\n\n\nWBC count (×103/μl)\n\n3.0\n8.3\n\n\n\nHemoglobin (g/dl)\n\n8.7\n9.4\n\n\n\nPlatelets (×103/μl)\n\n66.0\n347.0\n\n\n\nDysplastic granulocytes\n\nPseudo Pelger-Huet anomaly\nNo\n\n\n\nDysplastic erythrocytes\n\nMacrocytosis, Anisocytosis, Poikilocytosis, rare schistocyte\nDysplastic erythroid hyperplasia\n\n\n\nDysplastic megakaryocytes\n\nNo\nIncreased megakaryocytic proliferation with dysplasia\n\n\n\nChemotherapy\n\nFLAG-Ida-Ven, FLAG-Ven, completed\nAzacitidine, incomplete\n\n\n\nHSCT\n\nYes, allogeneic\nNo\n\n\n\nCR\n\nYes\nNo\n\n\n\nOS\n\n834 days s/p HSCT remains in CR\nDeceased 8 months later\n\n\n\nGene Mutations\n\n\nEZH2, SF3B1\n\n\nASXL1, DNMT3A, JAK2, SETBP1, SF3B1\n\n\n\n\n\nFLT3-ITD\n\nNegative\nNegative\n\n\n\n\nMECOM rearrangement\n\nPositive\nPositive\n\n\n\n\nETV6 rearrangement\n\nPositive\nPositive\n\n\n\nKaryogram\n\n46,XX,t(3;12)(q26.2;p13.1)[20]\n46,XY,t(3;12)(q26.2;p13.1),del(7)(q11.2q32)[10]/46,XY[10]\n\n\n\nOpen in a new tab\nCR, complete remission; FLT3-ITD, FLT3 internal tandem duplication; HSCT, hematopoietic stem cell transplant; OS, overall survival.Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Conventional cytogenetics, fluorescent in situ hybridization, and molecular genetics findings\nIn case #1, a conventional cytogenetics study observed a karyogram of 46,XX,t(3;12)(q26.2;p13.1)[20] (\nFigure 1A\n).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In case #2, a conventional cytogenetics study observed a karyogram of 46,XX,t(3;12)(q26.2;p13.1),del (7)(q11.2q32)[10/20] (\nFigure 2A\n).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Chromatin immunoprecipitation sequencing (ChIP-seq) studies on a human leukemia cell line SEM documented from ChEA2022 study (14), identified 18 of the 35 genes as putative targets of the transcription elongation factor AF4 (\nSupplementary Table 2\n, \nSupplementary Figure 2\n).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Enrichr-KG gene set enrichment analysis of these 38 genes showed that 20 of them are also targets of AF4 in SEM cells based on the ChIP-seq study (14) (\nSupplementary Figure 3\n).5.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Case 1\nCase 2\n\n\n\n\nAge at Diagnosis\n\n55\n74\n\n\n\nSex\n\nF\nM\n\n\n\nDiagnosis\n\nMDS with EB-2, with hypocellular AML transformation/progression\nMyeloid neoplasm with ringed sideroblasts\n\n\n\nBone marrow blasts (%)\n\n15% at diagnosis50% at AML transformation\n5-7%\n\n\n\nWBC count (×103/μl)\n\n3.0\n8.3\n\n\n\nHemoglobin (g/dl)\n\n8.7\n9.4\n\n\n\nPlatelets (×103/μl)\n\n66.0\n347.0\n\n\n\nDysplastic granulocytes\n\nPseudo Pelger-Huet anomaly\nNo\n\n\n\nDysplastic erythrocytes\n\nMacrocytosis, Anisocytosis, Poikilocytosis, rare schistocyte\nDysplastic erythroid hyperplasia\n\n\n\nDysplastic megakaryocytes\n\nNo\nIncreased megakaryocytic proliferation with dysplasia\n\n\n\nChemotherapy\n\nFLAG-Ida-Ven, FLAG-Ven, completed\nAzacitidine, incomplete\n\n\n\nHSCT\n\nYes, allogeneic\nNo\n\n\n\nCR\n\nYes\nNo\n\n\n\nOS\n\n834 days s/p HSCT remains in CR\nDeceased 8 months later\n\n\n\nGene Mutations\n\n\nEZH2, SF3B1\n\n\nASXL1, DNMT3A, JAK2, SETBP1, SF3B1\n\n\n\n\n\nFLT3-ITD\n\nNegative\nNegative\n\n\n\n\nMECOM rearrangement\n\nPositive\nPositive\n\n\n\n\nETV6 rearrangement\n\nPositive\nPositive\n\n\n\nKaryogram\n\n46,XX,t(3;12)(q26.2;p13.1)[20]\n46,XY,t(3;12)(q26.2;p13.1),del(7)(q11.2q32)[10]/46,XY[10]\n\n\n\nOpen in a new tab\nCR, complete remission; FLT3-ITD, FLT3 internal tandem duplication; HSCT, hematopoietic stem cell transplant; OS, overall survival.Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Conventional cytogenetics, fluorescent in situ hybridization, and molecular genetics findings\nIn case #1, a conventional cytogenetics study observed a karyogram of 46,XX,t(3;12)(q26.2;p13.1)[20] (\nFigure 1A\n).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In case #2, a conventional cytogenetics study observed a karyogram of 46,XX,t(3;12)(q26.2;p13.1),del (7)(q11.2q32)[10/20] (\nFigure 2A\n).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Chromatin immunoprecipitation sequencing (ChIP-seq) studies on a human leukemia cell line SEM documented from ChEA2022 study (14), identified 18 of the 35 genes as putative targets of the transcription elongation factor AF4 (\nSupplementary Table 2\n, \nSupplementary Figure 2\n).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Enrichr-KG gene set enrichment analysis of these 38 genes showed that 20 of them are also targets of AF4 in SEM cells based on the ChIP-seq study (14) (\nSupplementary Figure 3\n).5.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Case 1\nCase 2\n\n\n\n\nAge at Diagnosis\n\n55\n74\n\n\n\nSex\n\nF\nM\n\n\n\nDiagnosis\n\nMDS with EB-2, with hypocellular AML transformation/progression\nMyeloid neoplasm with ringed sideroblasts\n\n\n\nBone marrow blasts (%)\n\n15% at diagnosis50% at AML transformation\n5-7%\n\n\n\nWBC count (×103/μl)\n\n3.0\n8.3\n\n\n\nHemoglobin (g/dl)\n\n8.7\n9.4\n\n\n\nPlatelets (×103/μl)\n\n66.0\n347.0\n\n\n\nDysplastic granulocytes\n\nPseudo Pelger-Huet anomaly\nNo\n\n\n\nDysplastic erythrocytes\n\nMacrocytosis, Anisocytosis, Poikilocytosis, rare schistocyte\nDysplastic erythroid hyperplasia\n\n\n\nDysplastic megakaryocytes\n\nNo\nIncreased megakaryocytic proliferation with dysplasia\n\n\n\nChemotherapy\n\nFLAG-Ida-Ven, FLAG-Ven, completed\nAzacitidine, incomplete\n\n\n\nHSCT\n\nYes, allogeneic\nNo\n\n\n\nCR\n\nYes\nNo\n\n\n\nOS\n\n834 days s/p HSCT remains in CR\nDeceased 8 months later\n\n\n\nGene Mutations\n\n\nEZH2, SF3B1\n\n\nASXL1, DNMT3A, JAK2, SETBP1, SF3B1\n\n\n\n\n\nFLT3-ITD\n\nNegative\nNegative\n\n\n\n\nMECOM rearrangement\n\nPositive\nPositive\n\n\n\n\nETV6 rearrangement\n\nPositive\nPositive\n\n\n\nKaryogram\n\n46,XX,t(3;12)(q26.2;p13.1)[20]\n46,XY,t(3;12)(q26.2;p13.1),del(7)(q11.2q32)[10]/46,XY[10]\n\n\n\nOpen in a new tab\nCR, complete remission; FLT3-ITD, FLT3 internal tandem duplication; HSCT, hematopoietic stem cell transplant; OS, overall survival.Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Conventional cytogenetics, fluorescent in situ hybridization, and molecular genetics findings\nIn case #1, a conventional cytogenetics study observed a karyogram of 46,XX,t(3;12)(q26.2;p13.1)[20] (\nFigure 1A\n).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In case #2, a conventional cytogenetics study observed a karyogram of 46,XX,t(3;12)(q26.2;p13.1),del (7)(q11.2q32)[10/20] (\nFigure 2A\n).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Chromatin immunoprecipitation sequencing (ChIP-seq) studies on a human leukemia cell line SEM documented from ChEA2022 study (14), identified 18 of the 35 genes as putative targets of the transcription elongation factor AF4 (\nSupplementary Table 2\n, \nSupplementary Figure 2\n).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Enrichr-KG gene set enrichment analysis of these 38 genes showed that 20 of them are also targets of AF4 in SEM cells based on the ChIP-seq study (14) (\nSupplementary Figure 3\n).5.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Case 1\nCase 2\n\n\n\n\nAge at Diagnosis\n\n55\n74\n\n\n\nSex\n\nF\nM\n\n\n\nDiagnosis\n\nMDS with EB-2, with hypocellular AML transformation/progression\nMyeloid neoplasm with ringed sideroblasts\n\n\n\nBone marrow blasts (%)\n\n15% at diagnosis50% at AML transformation\n5-7%\n\n\n\nWBC count (×103/μl)\n\n3.0\n8.3\n\n\n\nHemoglobin (g/dl)\n\n8.7\n9.4\n\n\n\nPlatelets (×103/μl)\n\n66.0\n347.0\n\n\n\nDysplastic granulocytes\n\nPseudo Pelger-Huet anomaly\nNo\n\n\n\nDysplastic erythrocytes\n\nMacrocytosis, Anisocytosis, Poikilocytosis, rare schistocyte\nDysplastic erythroid hyperplasia\n\n\n\nDysplastic megakaryocytes\n\nNo\nIncreased megakaryocytic proliferation with dysplasia\n\n\n\nChemotherapy\n\nFLAG-Ida-Ven, FLAG-Ven, completed\nAzacitidine, incomplete\n\n\n\nHSCT\n\nYes, allogeneic\nNo\n\n\n\nCR\n\nYes\nNo\n\n\n\nOS\n\n834 days s/p HSCT remains in CR\nDeceased 8 months later\n\n\n\nGene Mutations\n\n\nEZH2, SF3B1\n\n\nASXL1, DNMT3A, JAK2, SETBP1, SF3B1\n\n\n\n\n\nFLT3-ITD\n\nNegative\nNegative\n\n\n\n\nMECOM rearrangement\n\nPositive\nPositive\n\n\n\n\nETV6 rearrangement\n\nPositive\nPositive\n\n\n\nKaryogram\n\n46,XX,t(3;12)(q26.2;p13.1)[20]\n46,XY,t(3;12)(q26.2;p13.1),del(7)(q11.2q32)[10]/46,XY[10]\n\n\n\nOpen in a new tab\nCR, complete remission; FLT3-ITD, FLT3 internal tandem duplication; HSCT, hematopoietic stem cell transplant; OS, overall survival.Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Conventional cytogenetics, fluorescent in situ hybridization, and molecular genetics findings\nIn case #1, a conventional cytogenetics study observed a karyogram of 46,XX,t(3;12)(q26.2;p13.1)[20] (\nFigure 1A\n).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In case #2, a conventional cytogenetics study observed a karyogram of 46,XX,t(3;12)(q26.2;p13.1),del (7)(q11.2q32)[10/20] (\nFigure 2A\n).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Chromatin immunoprecipitation sequencing (ChIP-seq) studies on a human leukemia cell line SEM documented from ChEA2022 study (14), identified 18 of the 35 genes as putative targets of the transcription elongation factor AF4 (\nSupplementary Table 2\n, \nSupplementary Figure 2\n).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Enrichr-KG gene set enrichment analysis of these 38 genes showed that 20 of them are also targets of AF4 in SEM cells based on the ChIP-seq study (14) (\nSupplementary Figure 3\n).5.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Case 1\nCase 2\n\n\n\n\nAge at Diagnosis\n\n55\n74\n\n\n\nSex\n\nF\nM\n\n\n\nDiagnosis\n\nMDS with EB-2, with hypocellular AML transformation/progression\nMyeloid neoplasm with ringed sideroblasts\n\n\n\nBone marrow blasts (%)\n\n15% at diagnosis50% at AML transformation\n5-7%\n\n\n\nWBC count (×103/μl)\n\n3.0\n8.3\n\n\n\nHemoglobin (g/dl)\n\n8.7\n9.4\n\n\n\nPlatelets (×103/μl)\n\n66.0\n347.0\n\n\n\nDysplastic granulocytes\n\nPseudo Pelger-Huet anomaly\nNo\n\n\n\nDysplastic erythrocytes\n\nMacrocytosis, Anisocytosis, Poikilocytosis, rare schistocyte\nDysplastic erythroid hyperplasia\n\n\n\nDysplastic megakaryocytes\n\nNo\nIncreased megakaryocytic proliferation with dysplasia\n\n\n\nChemotherapy\n\nFLAG-Ida-Ven, FLAG-Ven, completed\nAzacitidine, incomplete\n\n\n\nHSCT\n\nYes, allogeneic\nNo\n\n\n\nCR\n\nYes\nNo\n\n\n\nOS\n\n834 days s/p HSCT remains in CR\nDeceased 8 months later\n\n\n\nGene Mutations\n\n\nEZH2, SF3B1\n\n\nASXL1, DNMT3A, JAK2, SETBP1, SF3B1\n\n\n\n\n\nFLT3-ITD\n\nNegative\nNegative\n\n\n\n\nMECOM rearrangement\n\nPositive\nPositive\n\n\n\n\nETV6 rearrangement\n\nPositive\nPositive\n\n\n\nKaryogram\n\n46,XX,t(3;12)(q26.2;p13.1)[20]\n46,XY,t(3;12)(q26.2;p13.1),del(7)(q11.2q32)[10]/46,XY[10]\n\n\n\nOpen in a new tab\nCR, complete remission; FLT3-ITD, FLT3 internal tandem duplication; HSCT, hematopoietic stem cell transplant; OS, overall survival.Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Conventional cytogenetics, fluorescent in situ hybridization, and molecular genetics findings\nIn case #1, a conventional cytogenetics study observed a karyogram of 46,XX,t(3;12)(q26.2;p13.1)[20] (\nFigure 1A\n).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In case #2, a conventional cytogenetics study observed a karyogram of 46,XX,t(3;12)(q26.2;p13.1),del (7)(q11.2q32)[10/20] (\nFigure 2A\n).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Chromatin immunoprecipitation sequencing (ChIP-seq) studies on a human leukemia cell line SEM documented from ChEA2022 study (14), identified 18 of the 35 genes as putative targets of the transcription elongation factor AF4 (\nSupplementary Table 2\n, \nSupplementary Figure 2\n).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Enrichr-KG gene set enrichment analysis of these 38 genes showed that 20 of them are also targets of AF4 in SEM cells based on the ChIP-seq study (14) (\nSupplementary Figure 3\n).5.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Case 1\nCase 2\n\n\n\n\nAge at Diagnosis\n\n55\n74\n\n\n\nSex\n\nF\nM\n\n\n\nDiagnosis\n\nMDS with EB-2, with hypocellular AML transformation/progression\nMyeloid neoplasm with ringed sideroblasts\n\n\n\nBone marrow blasts (%)\n\n15% at diagnosis50% at AML transformation\n5-7%\n\n\n\nWBC count (×103/μl)\n\n3.0\n8.3\n\n\n\nHemoglobin (g/dl)\n\n8.7\n9.4\n\n\n\nPlatelets (×103/μl)\n\n66.0\n347.0\n\n\n\nDysplastic granulocytes\n\nPseudo Pelger-Huet anomaly\nNo\n\n\n\nDysplastic erythrocytes\n\nMacrocytosis, Anisocytosis, Poikilocytosis, rare schistocyte\nDysplastic erythroid hyperplasia\n\n\n\nDysplastic megakaryocytes\n\nNo\nIncreased megakaryocytic proliferation with dysplasia\n\n\n\nChemotherapy\n\nFLAG-Ida-Ven, FLAG-Ven, completed\nAzacitidine, incomplete\n\n\n\nHSCT\n\nYes, allogeneic\nNo\n\n\n\nCR\n\nYes\nNo\n\n\n\nOS\n\n834 days s/p HSCT remains in CR\nDeceased 8 months later\n\n\n\nGene Mutations\n\n\nEZH2, SF3B1\n\n\nASXL1, DNMT3A, JAK2, SETBP1, SF3B1\n\n\n\n\n\nFLT3-ITD\n\nNegative\nNegative\n\n\n\n\nMECOM rearrangement\n\nPositive\nPositive\n\n\n\n\nETV6 rearrangement\n\nPositive\nPositive\n\n\n\nKaryogram\n\n46,XX,t(3;12)(q26.2;p13.1)[20]\n46,XY,t(3;12)(q26.2;p13.1),del(7)(q11.2q32)[10]/46,XY[10]\n\n\n\nOpen in a new tab\nCR, complete remission; FLT3-ITD, FLT3 internal tandem duplication; HSCT, hematopoietic stem cell transplant; OS, overall survival.Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Conventional cytogenetics, fluorescent in situ hybridization, and molecular genetics findings\nIn case #1, a conventional cytogenetics study observed a karyogram of 46,XX,t(3;12)(q26.2;p13.1)[20] (\nFigure 1A\n).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In case #2, a conventional cytogenetics study observed a karyogram of 46,XX,t(3;12)(q26.2;p13.1),del (7)(q11.2q32)[10/20] (\nFigure 2A\n).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Chromatin immunoprecipitation sequencing (ChIP-seq) studies on a human leukemia cell line SEM documented from ChEA2022 study (14), identified 18 of the 35 genes as putative targets of the transcription elongation factor AF4 (\nSupplementary Table 2\n, \nSupplementary Figure 2\n).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Enrichr-KG gene set enrichment analysis of these 38 genes showed that 20 of them are also targets of AF4 in SEM cells based on the ChIP-seq study (14) (\nSupplementary Figure 3\n).5.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Case 1\nCase 2\n\n\n\n\nAge at Diagnosis\n\n55\n74\n\n\n\nSex\n\nF\nM\n\n\n\nDiagnosis\n\nMDS with EB-2, with hypocellular AML transformation/progression\nMyeloid neoplasm with ringed sideroblasts\n\n\n\nBone marrow blasts (%)\n\n15% at diagnosis50% at AML transformation\n5-7%\n\n\n\nWBC count (×103/μl)\n\n3.0\n8.3\n\n\n\nHemoglobin (g/dl)\n\n8.7\n9.4\n\n\n\nPlatelets (×103/μl)\n\n66.0\n347.0\n\n\n\nDysplastic granulocytes\n\nPseudo Pelger-Huet anomaly\nNo\n\n\n\nDysplastic erythrocytes\n\nMacrocytosis, Anisocytosis, Poikilocytosis, rare schistocyte\nDysplastic erythroid hyperplasia\n\n\n\nDysplastic megakaryocytes\n\nNo\nIncreased megakaryocytic proliferation with dysplasia\n\n\n\nChemotherapy\n\nFLAG-Ida-Ven, FLAG-Ven, completed\nAzacitidine, incomplete\n\n\n\nHSCT\n\nYes, allogeneic\nNo\n\n\n\nCR\n\nYes\nNo\n\n\n\nOS\n\n834 days s/p HSCT remains in CR\nDeceased 8 months later\n\n\n\nGene Mutations\n\n\nEZH2, SF3B1\n\n\nASXL1, DNMT3A, JAK2, SETBP1, SF3B1\n\n\n\n\n\nFLT3-ITD\n\nNegative\nNegative\n\n\n\n\nMECOM rearrangement\n\nPositive\nPositive\n\n\n\n\nETV6 rearrangement\n\nPositive\nPositive\n\n\n\nKaryogram\n\n46,XX,t(3;12)(q26.2;p13.1)[20]\n46,XY,t(3;12)(q26.2;p13.1),del(7)(q11.2q32)[10]/46,XY[10]\n\n\n\nOpen in a new tab\nCR, complete remission; FLT3-ITD, FLT3 internal tandem duplication; HSCT, hematopoietic stem cell transplant; OS, overall survival.Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Conventional cytogenetics, fluorescent in situ hybridization, and molecular genetics findings\nIn case #1, a conventional cytogenetics study observed a karyogram of 46,XX,t(3;12)(q26.2;p13.1)[20] (\nFigure 1A\n).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In case #2, a conventional cytogenetics study observed a karyogram of 46,XX,t(3;12)(q26.2;p13.1),del (7)(q11.2q32)[10/20] (\nFigure 2A\n).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Chromatin immunoprecipitation sequencing (ChIP-seq) studies on a human leukemia cell line SEM documented from ChEA2022 study (14), identified 18 of the 35 genes as putative targets of the transcription elongation factor AF4 (\nSupplementary Table 2\n, \nSupplementary Figure 2\n).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Enrichr-KG gene set enrichment analysis of these 38 genes showed that 20 of them are also targets of AF4 in SEM cells based on the ChIP-seq study (14) (\nSupplementary Figure 3\n).5.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Case 1\nCase 2\n\n\n\n\nAge at Diagnosis\n\n55\n74\n\n\n\nSex\n\nF\nM\n\n\n\nDiagnosis\n\nMDS with EB-2, with hypocellular AML transformation/progression\nMyeloid neoplasm with ringed sideroblasts\n\n\n\nBone marrow blasts (%)\n\n15% at diagnosis50% at AML transformation\n5-7%\n\n\n\nWBC count (×103/μl)\n\n3.0\n8.3\n\n\n\nHemoglobin (g/dl)\n\n8.7\n9.4\n\n\n\nPlatelets (×103/μl)\n\n66.0\n347.0\n\n\n\nDysplastic granulocytes\n\nPseudo Pelger-Huet anomaly\nNo\n\n\n\nDysplastic erythrocytes\n\nMacrocytosis, Anisocytosis, Poikilocytosis, rare schistocyte\nDysplastic erythroid hyperplasia\n\n\n\nDysplastic megakaryocytes\n\nNo\nIncreased megakaryocytic proliferation with dysplasia\n\n\n\nChemotherapy\n\nFLAG-Ida-Ven, FLAG-Ven, completed\nAzacitidine, incomplete\n\n\n\nHSCT\n\nYes, allogeneic\nNo\n\n\n\nCR\n\nYes\nNo\n\n\n\nOS\n\n834 days s/p HSCT remains in CR\nDeceased 8 months later\n\n\n\nGene Mutations\n\n\nEZH2, SF3B1\n\n\nASXL1, DNMT3A, JAK2, SETBP1, SF3B1\n\n\n\n\n\nFLT3-ITD\n\nNegative\nNegative\n\n\n\n\nMECOM rearrangement\n\nPositive\nPositive\n\n\n\n\nETV6 rearrangement\n\nPositive\nPositive\n\n\n\nKaryogram\n\n46,XX,t(3;12)(q26.2;p13.1)[20]\n46,XY,t(3;12)(q26.2;p13.1),del(7)(q11.2q32)[10]/46,XY[10]\n\n\n\nOpen in a new tab\nCR, complete remission; FLT3-ITD, FLT3 internal tandem duplication; HSCT, hematopoietic stem cell transplant; OS, overall survival.Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Conventional cytogenetics, fluorescent in situ hybridization, and molecular genetics findings\nIn case #1, a conventional cytogenetics study observed a karyogram of 46,XX,t(3;12)(q26.2;p13.1)[20] (\nFigure 1A\n).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In case #2, a conventional cytogenetics study observed a karyogram of 46,XX,t(3;12)(q26.2;p13.1),del (7)(q11.2q32)[10/20] (\nFigure 2A\n).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Chromatin immunoprecipitation sequencing (ChIP-seq) studies on a human leukemia cell line SEM documented from ChEA2022 study (14), identified 18 of the 35 genes as putative targets of the transcription elongation factor AF4 (\nSupplementary Table 2\n, \nSupplementary Figure 2\n).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Enrichr-KG gene set enrichment analysis of these 38 genes showed that 20 of them are also targets of AF4 in SEM cells based on the ChIP-seq study (14) (\nSupplementary Figure 3\n).5.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Case 1\nCase 2\n\n\n\n\nAge at Diagnosis\n\n55\n74\n\n\n\nSex\n\nF\nM\n\n\n\nDiagnosis\n\nMDS with EB-2, with hypocellular AML transformation/progression\nMyeloid neoplasm with ringed sideroblasts\n\n\n\nBone marrow blasts (%)\n\n15% at diagnosis50% at AML transformation\n5-7%\n\n\n\nWBC count (×103/μl)\n\n3.0\n8.3\n\n\n\nHemoglobin (g/dl)\n\n8.7\n9.4\n\n\n\nPlatelets (×103/μl)\n\n66.0\n347.0\n\n\n\nDysplastic granulocytes\n\nPseudo Pelger-Huet anomaly\nNo\n\n\n\nDysplastic erythrocytes\n\nMacrocytosis, Anisocytosis, Poikilocytosis, rare schistocyte\nDysplastic erythroid hyperplasia\n\n\n\nDysplastic megakaryocytes\n\nNo\nIncreased megakaryocytic proliferation with dysplasia\n\n\n\nChemotherapy\n\nFLAG-Ida-Ven, FLAG-Ven, completed\nAzacitidine, incomplete\n\n\n\nHSCT\n\nYes, allogeneic\nNo\n\n\n\nCR\n\nYes\nNo\n\n\n\nOS\n\n834 days s/p HSCT remains in CR\nDeceased 8 months later\n\n\n\nGene Mutations\n\n\nEZH2, SF3B1\n\n\nASXL1, DNMT3A, JAK2, SETBP1, SF3B1\n\n\n\n\n\nFLT3-ITD\n\nNegative\nNegative\n\n\n\n\nMECOM rearrangement\n\nPositive\nPositive\n\n\n\n\nETV6 rearrangement\n\nPositive\nPositive\n\n\n\nKaryogram\n\n46,XX,t(3;12)(q26.2;p13.1)[20]\n46,XY,t(3;12)(q26.2;p13.1),del(7)(q11.2q32)[10]/46,XY[10]\n\n\n\nOpen in a new tab\nCR, complete remission; FLT3-ITD, FLT3 internal tandem duplication; HSCT, hematopoietic stem cell transplant; OS, overall survival.Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Conventional cytogenetics, fluorescent in situ hybridization, and molecular genetics findings\nIn case #1, a conventional cytogenetics study observed a karyogram of 46,XX,t(3;12)(q26.2;p13.1)[20] (\nFigure 1A\n).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In case #2, a conventional cytogenetics study observed a karyogram of 46,XX,t(3;12)(q26.2;p13.1),del (7)(q11.2q32)[10/20] (\nFigure 2A\n).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Chromatin immunoprecipitation sequencing (ChIP-seq) studies on a human leukemia cell line SEM documented from ChEA2022 study (14), identified 18 of the 35 genes as putative targets of the transcription elongation factor AF4 (\nSupplementary Table 2\n, \nSupplementary Figure 2\n).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Enrichr-KG gene set enrichment analysis of these 38 genes showed that 20 of them are also targets of AF4 in SEM cells based on the ChIP-seq study (14) (\nSupplementary Figure 3\n).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Conventional cytogenetics, fluorescent in situ hybridization, and molecular genetics findings\nIn case #1, a conventional cytogenetics study observed a karyogram of 46,XX,t(3;12)(q26.2;p13.1)[20] (\nFigure 1A\n).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In case #2, a conventional cytogenetics study observed a karyogram of 46,XX,t(3;12)(q26.2;p13.1),del (7)(q11.2q32)[10/20] (\nFigure 2A\n).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In case #1, a conventional cytogenetics study observed a karyogram of 46,XX,t(3;12)(q26.2;p13.1)[20] (\nFigure 1A\n).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In case #2, a conventional cytogenetics study observed a karyogram of 46,XX,t(3;12)(q26.2;p13.1),del (7)(q11.2q32)[10/20] (\nFigure 2A\n).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Chromatin immunoprecipitation sequencing (ChIP-seq) studies on a human leukemia cell line SEM documented from ChEA2022 study (14), identified 18 of the 35 genes as putative targets of the transcription elongation factor AF4 (\nSupplementary Table 2\n, \nSupplementary Figure 2\n).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Enrichr-KG gene set enrichment analysis of these 38 genes showed that 20 of them are also targets of AF4 in SEM cells based on the ChIP-seq study (14) (\nSupplementary Figure 3\n).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Chromatin immunoprecipitation sequencing (ChIP-seq) studies on a human leukemia cell line SEM documented from ChEA2022 study (14), identified 18 of the 35 genes as putative targets of the transcription elongation factor AF4 (\nSupplementary Table 2\n, \nSupplementary Figure 2\n).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Enrichr-KG gene set enrichment analysis of these 38 genes showed that 20 of them are also targets of AF4 in SEM cells based on the ChIP-seq study (14) (\nSupplementary Figure 3\n).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  }
]